Relmada Therapeutics Appoints New Chief Medical Officer

Relmada Therapeutics ( (RLMD) ) has issued an update.

On June 17, 2025, Relmada Therapeutics announced the appointment of Raj S. Pruthi, MD as Chief Medical Officer-Urology. Dr. Pruthi, with over 25 years of experience in urologic oncology and clinical trials, will play a crucial role in advancing Relmada’s NDV-01 program for non-muscle invasive bladder cancer (NMIBC). The company aims to begin Phase 3 trials in the first half of 2026, following promising Phase 2 data presented at the American Urology Association 2025 Annual Meeting.

The most recent analyst rating on (RLMD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.

Spark’s Take on RLMD Stock

According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.

Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.

To see Spark’s full report on RLMD stock, click here.

More about Relmada Therapeutics

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

Average Trading Volume: 1,791,971

Technical Sentiment Signal: Sell

Current Market Cap: $23.5M

Find detailed analytics on RLMD stock on TipRanks’ Stock Analysis page.